

Special Issue

Molecular Research on Rare Thoracic Tumors

Message from the Guest Editors

Rare thoracic tumors include epithelial tumors of the trachea, rare epithelial tumors of the lung, epithelial tumors of the thymus, mesothelioma of pleura and pericardium, mediastinal germ cell tumors, neuroendocrine tumors of the thymus and lung, lymphoma of the mediastinum, and sarcoma of the thoracic cavity. These malignancies present an intrinsic complexity in the initial diagnostic phase, as well as in treatment choice, often due to unavailability of practice guidelines and the lack of data, which significantly limit treatment options. The systematic evaluation and definition of complex and uncommon thoracic tumors requires multidisciplinary team discussion in order to reach the correct diagnosis and offer the best treatment; therefore, the aim of this Special Issue is to collate significant recent results surrounding rare thoracic tumors.

Guest Editors

Dr. Giovannella Palmieri

Rare Tumors Coordinating Center of Campania Region (CRCTR),
Università degli Studi di Napoli Federico II, Naples, Italy

Dr. Mirella Marino

Department of Pathology, IRCCS Regina Elena National Cancer
Institute, Rome, Italy

Deadline for manuscript submissions

closed (31 January 2023)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/116790

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).